Last reviewed · How we verify
Phrenic nerve block with Ropivacaine
Ropivacaine blocks sodium channels in nerve fibers when injected around the phrenic nerve, temporarily interrupting nerve signal transmission to paralyze the diaphragm.
Ropivacaine, a local anesthetic, is used off-label for phrenic nerve blocks to manage postoperative shoulder pain. Clinical trials are ongoing to evaluate its efficacy and safety in various surgical contexts, including VATS and lobectomy.
At a glance
| Generic name | Phrenic nerve block with Ropivacaine |
|---|---|
| Also known as | Naropin |
| Sponsor | Odense University Hospital |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine is a local anesthetic that works by inhibiting voltage-gated sodium channels in nerve cell membranes, preventing depolarization and action potential propagation. When administered as a phrenic nerve block, it reversibly anesthetizes the phrenic nerve, which innervates the diaphragm, resulting in temporary diaphragmatic paralysis. This effect is used clinically to manage conditions such as intractable hiccups or to facilitate certain surgical procedures.
Approved indications
- Phrenic nerve block for diaphragmatic paralysis (e.g., intractable hiccups, surgical facilitation)
Common side effects
- Temporary diaphragmatic paralysis
- Hoarseness or voice changes
- Shoulder pain
- Local injection site reactions
- Systemic toxicity from local anesthetic (rare)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phrenic nerve block with Ropivacaine CI brief — competitive landscape report
- Phrenic nerve block with Ropivacaine updates RSS · CI watch RSS
- Odense University Hospital portfolio CI